In addition to this effect, the peptide is also used in medicine to treat various diseases such as chronic kidney failure and conditions related to low levels of growth hormone
Takahashi T, Takahashi T, et al
The synergy rationale extrapolates from: (1) documented synergy between GHRH and various GHRPs (particularly GHRP-6) across multiple species and systems, (2) individual characterization of CJC-1295 No DAC showing 49-fold potency enhancement, (3) individual characterization of Ipamorelin showing comparable potency to GHRP-6 but with superior selectivity, and (4) established mechanistic principles of complementary receptor pathway activation
The Advanced Recomp Stack combines retatrutide, CJC-1295 (No DAC), and ipamorelin in a 3-compound body recomposition protocol
Their unique properties present an opportunity for exploring physiological adaptations, receptor interactions, and molecular signaling mechanisms